Poging GOUD - Vrij
With $2.2 bn fund, ChrysCap has appetite for riskier bets
Mint Mumbai
|December 01, 2025
MD Saurabh Chatterjee details shift in global LP base, renewed focus on manufacturing
Saurabh Chatterjee, managing director, ChrysCapital.
After raising its largest-ever private equity (PE) fund of $2.2 billion, ChrysCapital is now open to taking higher-risk bets, said Saurabh Chatterjee, managing director (MD) at the firm.
“We've seen some other firms take risks that, at the time, we weren't comfortable taking. But they worked out really well for them. So now we're looking at whether there are specific situations where we, too, can take more risk,” said Chatterjee, who leads fundraising and limited partner (LP) relationships.
He said the firm’s risk appetite is rising in situations where ChrysCap can back companies with weaker operations, step in, fix them and create value.
This comes at a time when PE firms are actively scouting for buyouts of traditional, legacy businesses that have the potential to generate higher returns after restructuring.
PE firms typically target “an alpha of at least 4-5% above public market returns,” said Bharat Anand, senior partner at law firm Khaitan & Co.
Strategies vary by sector, deal size and capabilities. “Managers are fundamentally driven by the need to maximize returns and will not shy away from restructuring at the time of investment or exit”, if it improves outcomes, he added.
Dit verhaal komt uit de December 01, 2025-editie van Mint Mumbai.
Abonneer u op Magzter GOLD voor toegang tot duizenden zorgvuldig samengestelde premiumverhalen en meer dan 9000 tijdschriften en kranten.
Bent u al abonnee? Aanmelden
MEER VERHALEN VAN Mint Mumbai
Mint Mumbai
Gen Alpha will make new rules for their workplace
Gen Alpha will expect hybrid workplaces, Al tools and 4-day weeks— offices unrecognizable to their parents’
3 mins
December 01, 2025
Mint Mumbai
EC extends electoral roll revision by a week to II Dec; final list on 14 Feb
The Election Commission on Sunday extended by one week the entire schedule of the ongoing special intensive revision (SIR) of electoral rolls in nine states and three Union territories amid allegations by opposition parties that the “tight timelines” were creating problems for people and ground-level poll officials.
2 mins
December 01, 2025
Mint Mumbai
THE PROBLEM IS NOT JUST ABOUT DYNASTIC POLITICS
These days Tejashvi Yadav is the target of intense trolling. Before him the Huda family in Haryana and Thackerays in Maharashtra got the same treatment. So, is the battle of victory and defeat in electoral politics a tussle between dynasts vs the rest? Absolutely not.
3 mins
December 01, 2025
Mint Mumbai
Green hydrogen: Fast fashion could help bump up demand
A boom in its use for clean synthetic inputs might make a difference
3 mins
December 01, 2025
Mint Mumbai
Let's be a bit more selective in using the word 'reforms'
Everybody should take a beat and think before uttering the word ‘reforms’ the next time. Glib usage, frequently in the wrong context, threatens to rob the word of its import.
3 mins
December 01, 2025
Mint Mumbai
As mid-cap alpha shrinks, should you consider passive strategies?
Advisers urge a balanced mix—add passives slowly and back strong, active managers, as mid-caps are still pricey
4 mins
December 01, 2025
Mint Mumbai
With $2.2 bn fund, ChrysCap has appetite for riskier bets
MD Saurabh Chatterjee details shift in global LP base, renewed focus on manufacturing
3 mins
December 01, 2025
Mint Mumbai
GDP growth of 8% plus: How to sustain this pace
Last quarter's economic expansion has cheered India but the challenge is to sustain a brisk rate for years to come. For private investment to chip in, revive infrastructure partnerships
2 mins
December 01, 2025
Mint Mumbai
INSIDE INDIA'S ATTEMPT TO TAME DEEPFAKES
Detection tools today are not universal or consistent across languages
5 mins
December 01, 2025
Mint Mumbai
APIs to innovation: Bulk drug makers ramp up CDMO bets
Once focused on low-margin active pharmaceutical ingredients (APIs), India’s bulk drug manufacturers are raising their ambitions, with several now investing heavily in research and development to win contract development and manufacturing work from global drugmakers.
2 mins
December 01, 2025
Listen
Translate
Change font size

